Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology

被引:85
|
作者
D'Alto, Michele [1 ]
Romeo, Emanuele [1 ]
Argiento, Paola [1 ]
Sarubbi, Berardo [1 ]
Santoro, Giuseppe [1 ]
Grimaldi, Nicola [1 ]
Correra, Anna [1 ]
Scognamiglio, Giancarlo [1 ]
Russo, Maria Giovanna [1 ]
Calabro, Raffaele [1 ]
机构
[1] Univ Naples 2, Dept Cardiol, Monaldi Hosp, Naples, Italy
关键词
Pulmonary arterial hypertension; Congenital heart disease; Association therapy; IMPROVES FUNCTIONAL-CAPACITY; ORAL SILDENAFIL; COMBINATION THERAPY; INHALED ILOPROST; CLINICAL-TRIAL; ADULT PATIENTS; 6-MINUTE WALK; OPEN-LABEL; EFFICACY; TOLERABILITY;
D O I
10.1016/j.ijcard.2010.10.051
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The aim of the present study was to evaluate the safety, tolerability, clinical and haemodynamic impact of add-on sildenafil in patients with congenital heart disease (CHD)-related pulmonary arterial hypertension (PAH) and Eisenmenger physiology after failure of oral bosentan therapy. Methods: Thirty-two patients with CHD-related PAH (14 male, mean age 37.1 +/- 13.7 years) treated with oral bosentan underwent right heart catheterization (RHC) for clinical worsening. After RHC, all patients received oral sildenafil 20 mg thrice daily in addition to bosentan. Clinical status, resting transcutaneous oxygen saturation (SpO(2)), 6-minute walk test (6MWT), serology and RHC were assessed at baseline (before add-on sildenafil) and after 6 months of combination therapy. Results: Twelve patients had ventricular septal defect, 8 atrio-ventricular canal, 6 single ventricle, and 6 atrial septal defect. Twenty-eight/32 had Eisenmenger physiology and 4 (all with atrial septal defect) did not. All patients well tolerated combination therapy. After 6 months of therapy, an improvement in clinical status (WHO functional class 2.1 +/- 0.4 vs 2.9 +/- 0.3; P=0.042), 6-minute walk distance (360 +/- 51 vs 293 +/- 68 m; P=0.005), SpO(2) at the end of the 6MWT (72 +/- 10 vs 63 +/- 15%; P=0.047), Borg score (2.9 +/- 1.5 vs 4.4 +/- 2.3; P=0.036), serology (pro-brain natriuretic peptide 303 +/- 366 vs 760 +/- 943 pg/ml; P=0.008) and haemodynamics (pulmonary blood flow 3.4 +/- 1.0 vs 3.1 +/- 1.2 l/min/m(2), P=0.002; pulmonary vascular resistances index 19 +/- 9 vs 24 +/- 16 WU/m(2), P=0.003) was observed. Conclusions: Addition of sildenafil in adult patients with CHD-related PAH and Eisenmenger syndrome after oral bosentan therapy failure is safe and well tolerated at 6-month follow-up, resulting in a significant improvement in clinical status, effort SpO(2), exercise tolerance and haemodynamics. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
下载
收藏
页码:378 / 382
页数:5
相关论文
共 50 条
  • [41] Pulmonary arterial hypertension associated with congenital heart disease and Eisenmenger syndrome: current practice in pediatrics
    Frank, D. B.
    Hanna, B. D.
    MINERVA PEDIATRICA, 2015, 67 (02) : 169 - 185
  • [42] Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects
    Sitbon, O.
    Beghetti, M.
    Petit, J.
    Iserin, L.
    Humbert, M.
    Gressin, V.
    Simonneau, G.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2006, 36 : 25 - 31
  • [43] Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease
    Apostolopoulou, SC
    Manginas, A
    Cokkinos, DV
    Rammos, S
    HEART, 2005, 91 (11) : 1447 - 1452
  • [44] Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan
    Schuuring, Mark J.
    Vis, Jeroen C.
    Duffels, Marielle G.
    Bouma, Berto J.
    Mulder, Barbara J. M.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2010, 6 : 359 - 366
  • [45] Safety and tolerability of bosentan in patients with pulmonary hypertension secondary to congenital heart disease
    D'Alto, M.
    Sarubbi, B.
    Romeo, E.
    Santoro, G.
    Santarpia, G.
    Argiento, P.
    Russo, M. G.
    Calabro, R.
    EUROPEAN HEART JOURNAL, 2005, 26 : 77 - 77
  • [46] The effect of sildenafil on maternal mortality in pulmonary arterial hypertension associated with congenital heart disease
    Nahdi, N. S.
    Dinarti, L. K.
    Hartopo, A. B.
    Anggrahini, D. W.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [47] Safety, tolerability, clinical and haemodynamic impact of oral bosentan in patients with congenital heart disease related pulmonary hypertension or Eisenmenger syndrome and PWP > 15 mmHg
    D'alto, M.
    Romeo, E.
    Argiento, P.
    Sarubbi, B.
    Correra, A.
    Scognamiglio, G.
    Grimaldi, N.
    Russo, M. G.
    Calabro', R.
    EUROPEAN HEART JOURNAL, 2011, 32 : 113 - 113
  • [48] Consecutive use of sildenafil and bosentan for the treatment of pulmonary arterial hypertension associated with collagen vascular disease: sildenafil as reliever and bosentan as controller
    Kamata, Y.
    Iwamoto, M.
    Minota, S.
    LUPUS, 2007, 16 (11) : 901 - 903
  • [49] From bosentan to macitentan for pulmonary arterial hypertension and adult congenital heart disease: Further improvement?
    Blok, Ilja M.
    van Riel, Annelieke C. M. J.
    van Dijk, Arie P. J.
    Mulder, Barbara J. M.
    Bouma, Berto J.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 227 : 51 - 52
  • [50] Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy
    Porhownik, Nancy R.
    Al-Sharif, Hassan
    Bshouty, Zoheir
    CANADIAN RESPIRATORY JOURNAL, 2008, 15 (08) : 427 - 430